Eli Lilly Shared Detailed Results From ACHIEVE-3, the first head-to-head Phase 3 trial Of Orforglipron Compared With Oral Semaglutide, Outperforming Oral Semaglutide Across Primary And All Key Secondary Endpoints

Eli Lilly and Company -1.98%

Eli Lilly and Company

LLY

935.58

-1.98%

  • For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3
  • In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss
  • Lilly has submitted orforglipron to regulators in over 40 countries, with potential U.S. action for obesity in Q2 2026
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.